Xianhong Ou | Cardiovascular Pharmacology | Best Researcher Award

Posted on by Pencis

Dr. Xianhong Ou | Cardiovascular Pharmacology | Best Researcher Award

Mohammed Ahmed Akkaif | Cardiovascular Pharmacology | Best Researcher Award

Posted on by Pencis

Dr. Mohammed Ahmed Akkaif | Cardiovascular Pharmacology | Best Researcher Award

Dr. Mohammed Ahmed Akkaif, Fudan University, China

Dr. Mohammed Ahmed Akkaif is a Postdoctoral Researcher in the Department of Cardiology at Fudan University, China. He earned his Ph.D. in Clinical Pharmacy from Universiti Sains Malaysia in 2023, specializing in precision medicine, pharmacogenetics, and cardiology. A Young Ambassador for the European Association of Preventive Cardiology (2022–2024), he has published 34 peer-reviewed articles, with 29 indexed in SCI, and has over 2,179 citations. Recognized with the Young Researchers Award (ESC Asia 2022), he is a reviewer for 50+ high-impact journals. His research focuses on optimizing antithrombotic drug therapies through pharmacometabolomics for personalized cardiovascular treatment.

AUTHOR PROFILE

Scopus Profile

Orcid Profile

Google Scholar Profile

🎓EARLY ACADEMIC PURSUITS:

Dr. Mohammed Ahmed Akkaif began his academic journey with a strong foundation in Clinical Pharmacy at Universiti Sains Malaysia, where he completed his Doctor of Philosophy (PhD) in July 2023. During his PhD, he focused on the intersection of clinical pharmacy and biotechnology, gaining expertise in personalized and precision medicine. His academic accomplishments included publishing 10 articles (8 in SCI Q1 and Q2 journals) and presenting at six international conferences. This period also saw him design innovative approaches to enhance antithrombotic drug treatment, particularly through CYP2C19 genotype-guided antiplatelet therapy.

💼PROFESSIONAL ENDEAVORS:

Currently, Dr. Akkaif serves as a Postdoctoral Researcher in the Department of Cardiology at Fudan University’s Qingpu Branch of Zhongshan Hospital, China. His role involves leading advanced research in cardiovascular medicine, with a specialized focus on the clinical application of personalized medicine in cardiology. Additionally, he has served as a Young Ambassador for the European Association of Preventive Cardiology (EAPC) from 2022 to 2024, demonstrating his commitment to advancing heart health on a global scale. He has also contributed his expertise to several prestigious journals, with over 50 reviews in high-impact journals such as Journal of the American Heart Association and Arteriosclerosis, Thrombosis, and Vascular Biology.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR PHARMACOLOGY:

Dr. Akkaif’s research is primarily focused on pharmacogenetics and pharmacometabolomics, with a goal of improving personalized treatment strategies in cardiology. His work delves into the optimization of antithrombotic drug therapies through genetic and metabolic profiling, which holds the potential to revolutionize treatment protocols, making them more tailored to individual patient profiles. His research also bridges the gap between clinical pharmacy and biotechnology, aiming to develop more effective, individualized approaches to cardiovascular health.

🌍IMPACT AND INFLUENCE:

Dr. Akkaif’s contributions have already made a significant impact on both academic research and the practical application of precision medicine. He has been honored with the Young Researchers Award at the 2022 ESC Asia Conference in Singapore, highlighting his early recognition in the field. His research has also led to the publication of 34 peer-reviewed articles, with 29 of them indexed in SCI (Clarivate), reflecting his growing influence in the field of cardiovascular pharmacology. His work has contributed to advancing the understanding of genetic factors in drug response, and his findings are regularly cited by researchers and clinicians alike.

📚ACADEMIC CITATIONS AND RECOGNITION:

Dr. Akkaif’s publications have earned him considerable academic recognition, with a cumulative citation count of 2,179 as of now. This citation count reflects the profound influence his work has had on the scientific community, particularly in the areas of pharmacogenetics, pharmacometabolomics, and cardiology. His ability to produce impactful, high-quality research is evident through his consistent presence in top-tier journals, where his findings continue to shape the discourse on personalized medicine.

🌟LEGACY AND FUTURE CONTRIBUTIONS:

As Dr. Akkaif continues his postdoctoral work at Fudan University, his future contributions are poised to expand on his research in precision medicine and cardiology. Given his accomplishments thus far, his research promises to lead to more personalized treatment options for cardiovascular diseases, potentially transforming clinical practices and improving patient outcomes globally. His ongoing efforts in understanding the genetic and metabolic factors influencing drug efficacy will likely place him at the forefront of the personalized medicine movement, paving the way for future innovations in the medical field.

🏆KEY AWARDS AND HONORS:

  • Young Researchers Award at the 2022 ESC Asia Conference (Singapore)

  • Second Prize for the Young Investigator Award at the ESC Asia Congress in Singapore 2022

  • Young Ambassador of the European Association of Preventive Cardiology (EAPC) (2022–2024)

  • Reviewing Excellence for over 50 high-impact SCI Q1 and Q2 journals

🌍CONCLUSION:

Dr. Mohammed Ahmed Akkaif’s groundbreaking research in precision medicine and cardiology continues to shape the future of personalized healthcare. With a strong academic background, numerous publications, and recognition through prestigious awards, his work is making significant contributions to improving cardiovascular treatments. His role as a Young Ambassador for the European Association of Preventive Cardiology further highlights his dedication to global health. As he advances his postdoctoral research at Fudan University, Dr. Akkaif’s future endeavors hold the potential to revolutionize clinical practices, particularly in pharmacogenetics and pharmacometabolomics, ensuring more effective and individualized patient care.

TOP NOTABLE PUBLICATIONS:

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in …

Authors: AJ Ferrari, DF Santomauro, A Aali, YH Abate, C Abbafati, H Abbastabar, …

Journal: The Lancet

Year: 2024

Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease …

Authors: M Brauer, GA Roth, AY Aravkin, P Zheng, KH Abate, YH Abate, C Abbafati, …

Journal: The Lancet

Year: 2024

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the …

Authors: The Lancet

Year: 2024

Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050

Authors: M Naghavi, SE Vollset, KS Ikuta, LR Swetschinski, AP Gray, EE Wool, …

Journal: The Lancet

Year: 2024

Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021

Authors: SE Vollset, HS Ababneh, YH Abate, C Abbafati, R Abbasgholizadeh, …

Journal: The Lancet

Year: 2024

Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Authors: VL Feigin, MD Abate, YH Abate, S Abd ElHafeez, F Abd-Allah, …

Journal: The Lancet Neurology

Year: 2024

Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

Authors: NV Bhattacharjee, AE Schumacher, A Aali, YH Abate, R Abbasgholizadeh, …

Journal: The Lancet

Year: 2024

The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD)

Authors: MA Akkaif, NAA Daud, A Sha’aban, ML Ng, MAS Abdul Kader, DA Noor

Journal: Molecules

Year: 2021

A review of the effects of ticagrelor on adenosine concentration and its clinical significance

Authors: MA Akkaif, ML Ng, MASA Kader, NAA Daud, A Sha’aban, B Ibrahim

Journal: Pharmacological Reports

Year: 2021

National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990–2021, and forecasts up to 2050

Authors: M Ng, X Dai, RM Cogen, M Abdelmasseh, A Abdollahi, A Abdullahi, …

Journal: The Lancet

Year: 2024

 

Xiaodi Tang | Cardiovascular Medicine | Best Researcher Award

Posted on by Pencis

Dr. Xiaodi Tang | Cardiovascular Medicine | Best Researcher Award

Yongsub Choi | Cardiovascular Disease | Best Researcher Award

Posted on by Pencis

Dr. Yongsub Choi | Cardiovascular Disease | Best Researcher Award

Dr. Yongsub Choi, Bellin Memorial Hospital, South Korea

Dr. Yongsub Choi is a dedicated internal medicine physician at Bellin Memorial Hospital, Green Bay, WI. He completed his MBBS (Summa Cum Laude) from Harbin Medical University, China, and an Internal Medicine Residency at BronxCare Health System, NYC. With extensive research experience in cardiology, nephrology, and gastroenterology, he has contributed to advancements in ventricular arrhythmia, atrial fibrillation, and liver recovery. Dr. Choi’s diverse background includes leadership roles, international medical practice, and teaching. His commitment to patient care, research, and global healthcare improvement makes him a distinguished figure in the field of internal medicine.

AUTHOR PROFILE

Scopus Profile

Orcid Profile

🎓EARLY ACADEMIC PURSUITS:

Dr. Yongsub Choi’s academic journey is marked by excellence and dedication. He earned his Bachelor of Medicine, Bachelor of Surgery (MBBS) from Harbin Medical University, China, graduating Summa Cum Laude. His academic excellence was evident throughout his studies, securing the First Prize Scholarship multiple times (2008-2009, 2011-2014). Prior to his medical education, he pursued Theology and Anthropology at Don Bosco Center of Studies, Manila, Philippines, where he graduated Cum Laude. Additionally, he completed his Bachelor of Philosophy (B.Ph) at Gwangju Catholic University, South Korea.

🏥PROFESSIONAL ENDEAVORS:

Dr. Choi has built a dynamic and diverse career in internal medicine, research, and leadership. Currently, he serves as a Hospitalist at the Department of Internal Medicine, Apogee Physicians, Bellin Memorial Hospital, Green Bay, WI (April 2023 – Present). His previous medical roles include:

  • Resident Physician at BronxCare Health System, NYC, USA (Feb 2020 – Jan 2023)
  • Locum Intern at Savanna-La-Mar Public General Hospital, Jamaica (Jan – June 2019)

In addition to his medical career, he held leadership roles such as:

  • Acting Executive Director (Apr 2007 – Feb 2008) at International Cooperational Technical High School, Yanji, China
  • English Teacher at Baosigao Technical High School, Taiwan
  • Assistant Parish Priest at Gurosamdong Parish, South Korea
  • Private Soldier in the Republic of Korea Army, Cheolwon, South Korea

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR DISEASE:

Dr. Choi’s contributions to medical research have significantly impacted the fields of cardiology, nephrology, and gastroenterology. His research roles include:

Research Assistant – First Affiliated Hospital of Harbin Medical University, China

  • Investigated modulation of activated astrocytes in the hypothalamus paraventricular nucleus to prevent ventricular arrhythmia during acute myocardial infarction (July 2019 – Jan 2020).
  • Explored sonodynamic therapy for atrial fibrillation (AF) using a rabbit model (Mar 2017 – June 2018).
  • Studied mesenchymal stem cells with enhanced Bcl-2 expression to improve liver recovery in hepatic cirrhosis (July 2014 – Feb 2017).

Research Scholar – Albert Einstein College of Medicine, Bronx, NY

  • Focused on nephrology-related research under Dr. Victor L. Schuster, M.D. (June 2018 – Dec 2018).

🌍IMPACT AND INFLUENCE:

Dr. Choi’s work bridges clinical practice, academia, and international healthcare initiatives. His contributions extend beyond medical practice to mentorship, leadership, and medical education. His experience in multiple countries (USA, China, Jamaica, Taiwan, South Korea, and the Philippines) highlights his global perspective on healthcare and medical research.

🏅ACADEMIC CITES AND HONORS:

Dr. Choi has received numerous awards and recognitions:
Graduated Summa Cum Laude – Harbin Medical University (2014)
First Prize Scholarship (Top Student) – Harbin Medical University (2008-09, 2011-14)
Secretary of Class of 2008 – Harbin Medical University (2012-2014)
Cum Laude – Don Bosco Center of Studies, Manila, Philippines (2001)

🚀LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Choi continues to shape the future of internal medicine and medical research. His extensive experience in cardiology, nephrology, and gastroenterology positions him as a key contributor to advancements in patient care and treatment methodologies. Moving forward, he aims to:

Enhance clinical excellence through evidence-based medicine.
Contribute to medical education and mentorship.
Advance research in cardiovascular and metabolic diseases.
Improve healthcare accessibility and quality in underprivileged regions.

 🌟CONCLUSION:

Dr. Yongsub Choi’s journey is a testament to dedication, excellence, and global impact in internal medicine and research. His expertise in cardiology, nephrology, and gastroenterology has contributed to significant advancements in patient care. With a strong foundation in clinical practice, leadership, and education, he continues to inspire future medical professionals. His commitment to evidence-based medicine, mentorship, and international healthcare development reflects his passion for improving lives worldwide. As he moves forward, Dr. Choi remains a trailblazer in internal medicine, striving for innovation and excellence in patient care and medical research.

TOP NOTABLE PUBLICATION

Probability assessment of pulmonary embolism using clinical and laboratory variables in hospitalized patients: A single-center, retrospective observational study

Authors: Y. Choi, Yongsub; N. Prasai, Neeti; T. Bhatt, Tanushree; A. Latif, Amber; M. Khaja, Misbahuddin

Journal: Thrombosis Update

Year: 2024

Yan Pan | Kawasaki disease | Best Researcher Award

Posted on by Pencis

Mr. Yan Pan | Kawasaki disease | Best Researcher Award

Mr. Yan Pan, The First Affiliated Hospital of Yangtze University, China

Mr. Yan Pan is a distinguished pediatrician at The First Affiliated Hospital of Yangtze University, China, specializing in Kawasaki disease. He serves as Deputy Chief Physician of Pediatrics and Chief Expert of the Kawasaki Disease MDT Team. A Fellow of the Royal Society of Arts and Crafts (RSA, UK), he is Deputy Editor-in-Chief of the International Journal of Pediatrics (2023). With 10 SCI-indexed publications, he has led multiple research projects and contributed to China’s 2023 Kawasaki Disease Treatment Guidelines. Recognized with awards for pediatric research excellence, he continues to advance pediatric infectious disease diagnosis and treatment globally.

AUTHOR PROFILE

Google Scholar Profile

🎓EARLY ACADEMIC PURSUITS:

Mr. Yan Pan pursued a strong academic foundation in pediatrics, focusing on childhood diseases and immunological disorders. His passion for medical research led him to specialize in Kawasaki disease, a rare but serious pediatric illness. His early education and training laid the groundwork for his later contributions to pediatric medicine and innovative treatments.

🏥PROFESSIONAL ENDEAVORS:

Currently, Mr. Yan Pan serves as the Deputy Chief Physician of Pediatrics at The First Affiliated Hospital of Yangtze University in China. He is the Chief Expert of the Kawasaki Disease MDT Team, where he plays a crucial role in diagnosing and treating Kawasaki disease. In 2023, he was appointed Deputy Editor-in-Chief of the International Journal of Pediatrics, contributing significantly to the field through editorial leadership and research dissemination.

🔍CONTRIBUTIONS AND RESEARCH FOCUS ON KAWASAKI DISEASE:

Mr. Yan Pan has been actively involved in numerous scientific research projects, including:

  • Hosting a project for the Hubei Pediatric Medical Alliance (2021), which received an excellent completion rating.
  • Leading two research projects in Jingzhou City, one of which won third prize in the Jingzhou City Natural Science Excellent Academic Paper Award (2020).
  • Contributing to a major research project at the Wuhan Science and Technology Bureau, which is currently ongoing.
  • Collaborating with the Kawasaki Disease Center at Chang Gung Memorial Hospital, Taiwan, to advance treatment protocols and research.

His research primarily focuses on pediatric infections and immunity, particularly Kawasaki disease, aiming to enhance diagnostic accuracy and treatment efficacy.

🌍IMPACT AND INFLUENCE:

His influence extends beyond clinical practice and research. He is recognized as:

  • A Fellow of the Royal Society of Arts and Crafts (RSA), UK.
  • A China National Knowledge Infrastructure (CNKI) Evaluation Expert.
  • An Expert of the China Pharmaceutical Innovation Industry Science and Technology Service Team for Science and Technology Innovation.

His expertise has shaped clinical guidelines and treatment protocols, directly impacting the pediatric community in China and beyond.

📚ACADEMIC CITATIONS AND RECOGNITION:

  • 10 SCI-indexed articles published as first author or corresponding author.
  • Awarded “Best Researcher” in Pediatric Infection and Immunity (2023), organized by Science Father.
  • Recognized as an Excellent Scientific and Technological Worker at the Kawasaki Disease Diagnosis and Treatment Research Center in Shaanxi Province (2023).
  • Winner of the Best Outstanding Paper of the Year (2023) by Discussion of Clinical Cases Magazine.

🚀LEGACY AND FUTURE CONTRIBUTIONS:

Mr. Yan Pan’s lasting contributions to pediatric medicine include his role in compiling the “Evidence-Based Treatment Guidelines for Kawasaki Disease in Chinese Children (2023 Edition)”. His continued research and dedication to improving diagnostic and treatment methodologies ensure that his impact will be felt for generations to come.

His future focus remains on enhancing Kawasaki disease treatment, expanding research collaborations, and mentoring the next generation of pediatricians to advance medical knowledge and patient care.

🌟CONCLUSION:

Mr. Yan Pan is a leading pediatrician dedicated to advancing the diagnosis and treatment of Kawasaki disease in children. His contributions to research, clinical practice, and medical guidelines  have significantly improved pediatric healthcare. As a renowned expert and mentor , he continues to shape the future of pediatric infectious disease treatment. With numerous awards, publications, and leadership roles , his impact extends beyond China to the global medical community . Through his dedication and innovation, Mr. Yan Pan remains a driving force in ensuring better health outcomes for children worldwide.

TOP NOTABLE PUBLICATIONS

Title: Anal swab findings in an infant with COVID-19
Authors: Q Fan, Y Pan, Q Wu, S Liu, X Song, Z Xie, Y Liu, L Zhao, Z Wang, Y Zhang, …
Journal: Pediatric Investigation
Year: 2020

Title: The M235T polymorphism in the angiotensinogen gene and myocardial infarction risk: A meta-analysis
Authors: YJ Wang, Y Pan
Journal: Journal of the Renin-Angiotensin-Aldosterone System
Year: 2014

Title: Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to Kawasaki disease: a meta-analysis
Authors: Y Pan, H Lu
Journal: African Health Sciences
Year: 2017

Title: Treatment of immunoglobulin-resistant Kawasaki disease: a Bayesian network meta-analysis of different regimens
Authors: Y Pan, Q Fan, L Hu
Journal: Frontiers in Pediatrics
Year: 2023

Title: Identification of potential core genes in immunoglobulin-resistant Kawasaki disease using bioinformatics analysis
Authors: Y Pan, Q Fan
Journal: Critical Reviews™ in Eukaryotic Gene Expression
Year: 2020

Title: Guideline for the diagnosis and treatment of incomplete Kawasaki disease in children in China
Authors: F Jiao, Y Pan, Z Du, F Deng, X Yang, H Wang, J Shen, W Xiang, Z Mu, …
Journal: BMC Pediatrics
Year: 2024

Title: The role of procalcitonin for predicting Kawasaki disease
Authors: Y Pan, Q Fan
Journal: Fetal and Pediatric Pathology
Year: 2022

Title: Clostridium symbiosum sepsis diagnosed using next-generation sequencing in a 2-year-old child: a case report
Authors: Y Pan, Q Fan
Journal: Fetal and Pediatric Pathology
Year: 2023

Title: Application of artificial intelligence in the diagnosis and treatment of Kawasaki disease
Authors: Y Pan, FY Jiao
Journal: World Journal of Clinical Cases
Year: 2024

Title: Relationship between Kawasaki disease and abdominal pain
Authors: Y Pan, FY Jiao
Journal: World Journal of Clinical Cases
Year: 2024

Yao An | Thrombosis | Best Researcher Award

Posted on by Pencis

Mr. Yao An | Thrombosis | Best Researcher Award

Wei Eric Wang | Myocardial Infarction | Best Researcher Award

Posted on by Pencis

Prof. Wei Eric Wang | Myocardial Infarction | Best Researcher Award

Prof. Wei Eric Wang, Southwest Hospital, Army Medical University, China

Prof. Wei Eric Wang is a distinguished medical professional based at Southwest Hospital, Army Medical University, in China. Renowned for his expertise in medical research and clinical practice, he has contributed significantly to the fields of surgery, healthcare management, and medical education. With numerous publications in peer-reviewed journals, Prof. Wang has established a reputation for pioneering studies in his area of specialization. He is also actively involved in advancing medical training, and his leadership at the hospital continues to shape healthcare innovation in China. His work has earned him recognition both nationally and internationally.

AUTHOR PROFILE

Scopus

Orcid

🎓EARLY ACADEMIC PURSUITS:

Dr. Wei (Eric) Wang pursued his medical education at the Third Military Medical University in Chongqing, China. He earned his M.D. in Clinical Medicine from 2000 to 2005. Following this, he completed his Ph.D. at the Institute of Burn Surgery, Southwest Hospital, at the same university between 2005 and 2010. His early academic endeavors laid the foundation for his expertise in cardiology and geriatric medicine.

🏥PROFESSIONAL ENDEAVORS:

Dr. Wang has held various prestigious positions throughout his career. He has been the Director of the Department of Geriatrics at Southwest Hospital since November 2022, demonstrating his leadership in the field. Prior to this, he served as Chief Physician and Professor in the Department of Cardiology at Daping Hospital, Army Medical University. His extensive experience includes roles such as Deputy Director, Associate Chief Physician, Attending Doctor, and Resident, reflecting his progressive career growth and expertise in cardiology and geriatrics.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON Myocardial Infarction

Dr. Wang’s research is centered on new strategies for treating cardiovascular diseases, particularly myocardial infarction and heart failure. His primary areas of focus include:

  1. Mechanisms regulating cardiac regeneration.
  2. Translational and clinical studies for treating cardiovascular diseases.
  3. Translational and clinical research for preventing aging.

His work has significantly advanced the understanding of cardiac repair mechanisms and potential therapeutic interventions.

🌍IMPACT AND INFLUENCE:

Dr. Wang has played a crucial role in the field of cardiology and geriatrics. His research has contributed to innovative treatments that enhance cardiac regeneration and improve patient outcomes. As a leader in cardiovascular medicine, his influence extends beyond clinical practice to shaping future medical research and treatment methodologies.

📚ACADEMIC CITATIONS AND RECOGNITION:

Dr. Wang has an impressive list of publications in esteemed medical journals. Some of his notable works include:

  1. “Metabolic reprogramming: a byproduct or a driver of cardiomyocyte proliferation?” published in Circulation (2024).
  2. “Loss of NPPA-AS1 promotes heart regeneration by stabilizing SFPQ-NONO heteromer-induced DNA repair,” published in Basic Research in Cardiology (2022).
  3. “The Role of G Protein-Coupled Receptor Kinase 4 in Cardiomyocyte Injury after Myocardial Infarction,” published in European Heart Journal (2021).
  4. “Dedifferentiation, Proliferation, and Redifferentiation of Adult Mammalian Cardiomyocytes After Ischemic Injury,” published in Circulation (2017).

These publications highlight his extensive contributions to cardiovascular research and his role in advancing medical knowledge in this domain.

🌟LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Wang’s legacy is deeply rooted in his contributions to cardiovascular research, innovative treatment strategies, and leadership in geriatric medicine. As a distinguished professor and researcher, his work continues to shape the future of cardiology and geriatrics. His ongoing research and clinical innovations are expected to provide new breakthroughs in cardiac care and aging prevention, benefiting future generations of patients and medical professionals.

🚀CONCLUSION:

Prof. Wei Eric Wang is a distinguished cardiologist and geriatrician whose groundbreaking research and leadership have significantly impacted cardiovascular medicine. His dedication to innovation, patient care, and scientific discovery continues to inspire future generations. As Director of Geriatrics at Southwest Hospital, his work advances both clinical and translational medicine, improving lives worldwide. With numerous influential publications and a commitment to pioneering treatments, his contributions to cardiac regeneration and aging prevention are invaluable. His legacy in medicine and academia ensures a lasting impact, shaping the future of healthcare and research.

TOP NOTABLE PUBLICATIONS

  • Title: Metabolic Reprogramming: A Byproduct or a Driver of Cardiomyocyte Proliferation?
    Authors: Xiaokang Chen, Hao Wu, Ya Liu, Lingyan Liu, Steven R. Houser, Wei Eric Wang
    Journal: Circulation
    Year: 2024

  • Title: Loss of NPPA-AS1 promotes heart regeneration by stabilizing SFPQ–NONO heteromer-induced DNA repair
    Authors: Wenbin Fu, Hongmei Ren, Jialing Shou, Qiao Liao, Liangpeng Li, Yu Shi, Pedro A. Jose, Chunyu Zeng, Wei Eric Wang
    Journal: Basic Research in Cardiology
    Year: 2022

  • Title: The Protective Role of Yin‐Yang 1 in Cardiac Injury and Remodeling After Myocardial Infarction
    Authors: Yu Huang, Liangpeng Li, Hongmei Chen, Qiao Liao, Xiaoli Yang, Dezhong Yang, Xuewei Xia, Hongyong Wang, Wei Eric Wang, Lianglong Chen et al.
    Journal: Journal of the American Heart Association
    Year: 2021

  • Title: The role of G protein-coupled receptor kinase 4 in cardiomyocyte injury after myocardial infarction
    Authors: Wei Eric Wang, Liangpeng Li, Fu W, Gong X, Chen Z, Tang L, Yang D, Liao Q, Xia X, Wu H et al.
    Journal: European Heart Journal
    Year: 2021

  • Title: An Aurora Kinase B-Based Mouse System to Efficiently Identify and Analyze Proliferating Cardiomyocytes
    Authors: Wei Eric Wang, Fu W, Liao Q, Li L, Shi Y, Zeng A, Zeng C, Wang WE
    Journal: Frontiers in Cell and Developmental Biology
    Year: 2020

  • Title: Cardiomyocyte PKA Ablation Enhances Basal Contractility While Eliminates Cardiac β-Adrenergic Response Without Adverse Effects on the Heart
    Authors: Wei Eric Wang, Zhang Y, Wang WE, Zhang X, Li Y, Chen B, Liu C, Ai X, Zhang X, Tian Y et al.
    Journal: Circulation Research
    Year: 2019

  • Title: Noncoding RNA and Cardiomyocyte Proliferation
    Authors: Shuang Qu, Chunyu Zeng, Wei Eric Wang
    Journal: Stem Cells International
    Year: 2017

  • Title: Dedifferentiation, Proliferation, and Redifferentiation of Adult Mammalian Cardiomyocytes After Ischemic Injury
    Authors: Wei Eric Wang, Wang WE, Li L, Xia X, Fu W, Liao Q, Lan C, Yang D, Chen H, Yue R et al.
    Journal: Circulation
    Year: 2017

  • Title: Prolyl hydroxylase domain protein 2 silencing enhances the survival and paracrine function of transplanted adipose-derived stem cells in infarcted myocardium
    Authors: Wei Eric Wang, Wang WE, Yang D, Li L, Wang W, Peng Y, Chen C, Chen P, Xia X, Wang H et al.
    Journal: Circulation Research
    Year: 2013

Wang Yanqiang | Atherosclerosis | Best Researcher Award

Posted on by Pencis

Prof. Wang Yanqiang | Atherosclerosis | Best Researcher Award

Prof. Wang Yanqiang, Department of Neurology Ⅱ, The Affiliated Hospital of Shandong Second Medical University, China

Prof. Wang Yanqiang is a distinguished neurologist currently serving in the Department of Neurology II at the Affiliated Hospital of Shandong Second Medical University, China. With a strong academic background, Prof. Wang earned his Master’s degree in Neurology from Xu Zhou Medical University and a Ph.D. from Sun Yat-sen University. His research primarily focuses on the pathogenesis and neuroprotection of ischemic brain injury, Parkinson’s disease, and other cerebrovascular disorders. Over the years, Prof. Wang has held various key positions, including roles as a resident and attending doctor at leading medical institutions in China.

AUTHOR PROFILE

Orcid Profile

🎓EARLY ACADEMIC PURSUITS:

Prof. Wang Yanqiang began his academic journey in the field of neurology, focusing on understanding the intricacies of neurological disorders and brain function. He pursued his medical education and specialized in neurology, laying the foundation for his future contributions in this domain. His early academic training focused on acquiring deep knowledge of neurophysiology, clinical neurology, and neuroanatomy, which would later guide his professional endeavors.

🏥PROFESSIONAL ENDEAVORS:

Prof. Wang Yanqiang holds a distinguished position at the Department of Neurology II at The Affiliated Hospital of Shandong Second Medical University, China. Over the years, he has been a leading figure in both clinical practice and medical research. He has worked tirelessly in patient care, offering specialized neurological treatments and providing critical insights into various neurological conditions. His professional endeavors also include educating and mentoring students, fostering the next generation of neurologists, and playing a key role in advancing clinical practices within the medical community.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON Atherosclerosis

Prof. Wang Yanqiang’s research primarily revolves around neurological disorders, with a particular focus on neurodegenerative diseases, cerebrovascular disorders, and epilepsy. His contributions to the understanding of these diseases have led to significant advancements in both diagnostic techniques and treatment methodologies. His research also spans neuroplasticity, neuroinflammation, and neuroprotective strategies, aiming to develop better therapeutic approaches for patients suffering from neurological impairments. Additionally, Prof. Wang has contributed to the development of diagnostic tools that have improved clinical outcomes in neurology.

🌍IMPACT AND INFLUENCE:

Prof. Wang Yanqiang’s work has had a profound impact on the field of neurology in both China and internationally. His contributions to the understanding of complex neurological diseases have shaped modern clinical practices and research initiatives. His publications and research findings have influenced treatment protocols and inspired further studies in neurodegenerative and cerebrovascular diseases. As a prominent figure in neurology, Prof. Wang has served as a role model for younger neurologists, encouraging a new wave of innovative thinking and patient-centered care in neurology.

📚ACADEMIC CITATIONS AND RECOGNITION:

Prof. Wang Yanqiang’s research has been widely recognized and cited within the academic community. His articles and studies are frequently cited in major neurological journals, reflecting the significance of his work in advancing scientific knowledge in neurology. His contributions have earned him a reputation as a leading expert in the field, with many of his works becoming foundational references for ongoing research. His academic influence is evidenced not only by citations but also through his collaborations with prominent neurologists worldwide.

🌟LEGACY AND FUTURE CONTRIBUTIONS:

Prof. Wang Yanqiang’s legacy in the field of neurology is marked by his groundbreaking research, dedication to patient care, and commitment to advancing the field. His work has contributed to a better understanding of neurological diseases and has paved the way for innovative treatments. As the field of neurology continues to evolve, Prof. Wang’s influence will likely continue to shape future developments in both clinical practice and medical research. His legacy also includes the mentorship of future generations of neurologists, ensuring that his impact on the field will extend far beyond his career.

🚀CONCLUSION:

Prof. Wang Yanqiang is an esteemed neurologist whose research has greatly advanced our understanding of ischemic brain injury, Parkinson’s disease, and cerebrovascular disorders. With a rich academic background and extensive clinical experience, his contributions to neuroprotection and molecular mechanisms are highly impactful. Through his numerous publications, Prof. Wang has gained international recognition for his work, which continues to influence the field of neurology. His dedication to improving patient outcomes and advancing neurological research makes him a true leader in the medical community.

TOP NOTABLE PUBLICATIONS

  • Title: Inhibition of the cGAS–STING pathway: contributing to the treatment of cerebral ischemia-reperfusion injury

    • Journal: Neural Regeneration Research
    • Volume: 2025-07
    • Year: 2025

  • Title: Exploring the Neuroprotective Effects of Lithium in Ischemic Stroke: A literature review

    • Journal: International Journal of Medical Sciences
    • Volume: 2024
    • Year: 2024

  • Title: Risk Factors and Clinical Characteristics of First-ever Ischemic Stroke Caused by ICAS with Leukoaraiosis

    • Journal: International Journal of Medical Sciences
    • Volume: 2024
    • Year: 2024

  • Title: 1,25-D3 ameliorates ischemic brain injury by alleviating endoplasmic reticulum stress and ferroptosis: Involvement of vitamin D receptor and p53 signaling

    • Journal: Cellular Signalling
    • Volume: 2024-10
    • Year: 2024

  • Title: A case of acute basilar artery occlusion due to atherosclerotic disease revascularized by drug-coated balloon dilation

    • Journal: International Journal of Neuroscience
    • Volume: 2024-09
    • Year: 2024

  • Title: A case report of drug-coated balloon dilation angioplasty in a patient with acute atherosclerotic basilar artery occlusion

    • Journal: Asian Journal of Surgery
    • Volume: 2024-09
    • Year: 2024

  • Title: Global, regional, and national epidemiology of ischemic stroke from 1990 to 2021

    • Journal: European Journal of Neurology
    • Volume: 2024-09-17
    • Year: 2024

  • Title: Genetic insights into the relationship between immune cell characteristics and ischemic stroke: A bidirectional Mendelian randomization study

    • Journal: European Journal of Neurology
    • Volume: 2024-05
    • Year: 2024

  • Title: Assessing tobacco-related ischemic stroke in Pakistan (1990-2019): Insights from the Global Burden of Disease Study

    • Journal: Tobacco Induced Diseases
    • Volume: 2024-03-28
    • Year: 2024

  • Title: First report of a p.Cys484Tyr Notch3 mutation in a CADASIL patient with acute bilateral multiple subcortical infarcts—case report and brief review

    • Journal: BMC Neurology
    • Year: 2024

Bing Li | Endocarditis | Best Researcher Award

Posted on by Pencis

Dr. Bing Li | Endocarditis | Best Researcher Award

Dr. Bing Li, Chinese PLA General Hospital First Medical Center, China

Dr. Bing Li is an Associate Chief Physician at The First Medical Center, Chinese PLA General Hospital, Beijing, China. He holds a Ph.D. in Endocrinology and Metabolism from PLA Medical College (2020) and has a Master’s Degree (2013) in the same field. His expertise includes diabetes, thyroid disorders, metabolic syndrome, and endocrine diseases. Dr. Li is actively involved in clinical practice, research, and medical education, contributing to advanced treatments and diagnostic techniques. His work has been published in leading medical journals, making a significant impact on endocrinology and metabolic disease management in China.

AUTHOR PROFILE

Scopus Profile

🎓EARLY ACADEMIC PURSUITS:

Dr. Bing Li’s academic journey began with a Bachelor’s Degree in Clinical Medicine from Hebei Medical University (2005–2010), where he laid the foundation for his expertise in the medical field. His passion for endocrinology and metabolism led him to pursue a Master’s Degree at PLA Medical College (2010–2013), further deepening his understanding of metabolic disorders and endocrine health. His dedication culminated in a Ph.D. in Endocrinology and Metabolism (2016–2020), where he focused on advanced research in hormonal and metabolic diseases.

🏥PROFESSIONAL ENDEAVORS:

Currently serving as an Associate Chief Physician at The First Medical Center, Chinese PLA General Hospital, Beijing, Dr. Li plays a crucial role in treating and managing complex endocrine disorders. His expertise spans diabetes, thyroid diseases, adrenal disorders, and metabolic syndromes, making him a key figure in China’s medical landscape.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON ENDOCARDITIS:

Dr. Li’s research primarily revolves around:

  • Diabetes and Insulin Resistance 🩸
  • Thyroid Disorders and Hormonal Imbalances 🦋
  • Adrenal and Pituitary Gland Diseases 🔄
  • Metabolic Syndrome and Obesity-Related Conditions ⚖️

His work aims to improve diagnostic techniques, enhance treatment protocols, and develop innovative therapeutic strategies for endocrine disorders. Through his research, he has contributed to clinical advancements in the management of metabolic diseases.

🌍IMPACT AND INFLUENCE:

Dr. Bing Li has made significant contributions to the Chinese medical community, particularly in endocrinology and metabolic medicine. As an Associate Chief Physician, he has influenced:

  • Clinical practices by integrating research-based solutions
  • Medical education through mentoring young doctors and researchers
  • Public health awareness on diabetes prevention and treatment

His work has helped shape medical guidelines and policies, ensuring improved patient outcomes in China and beyond.

📚ACADEMIC CITATIONS AND RECOGNITION:

Dr. Li’s scientific publications in high-impact medical journals have been widely cited by researchers and clinicians. His studies on endocrine disorders, metabolic regulation, and hormone-related diseases are highly regarded in the medical community.

🌟LEGACY AND FUTURE CONTRIBUTIONS:

With a strong foundation in endocrinology, Dr. Bing Li is set to expand his influence in medical research, clinical innovation, and public health policy. His future endeavors may include:
✅ Leading cutting-edge research in precision medicine for endocrine disorders
✅ Collaborating on international studies to enhance metabolic disease treatment
✅ Developing new medical technologies for early diagnosis and personalized therapy

Dr. Li’s dedication to medical excellence ensures that his legacy in endocrinology will continue to impact future generations of physicians and researchers.

🚀CONCLUSION:

Dr. Bing Li’s dedication to endocrinology and metabolic research has significantly impacted clinical practice, medical education, and patient care. His expertise in diabetes, thyroid disorders, and metabolic diseases continues to shape advanced treatments and innovative diagnostic approaches. As an Associate Chief Physician, he plays a vital role in improving healthcare outcomes in China. With his commitment to scientific progress and medical excellence, Dr. Li’s influence will extend to future generations of physicians and researchers. His work ensures better disease management, improved therapies, and enhanced patient well-being for years to come.

TOP NOTABLE PUBLICATIONS

Association Between Skin Autofluorescence and Coronary Heart Disease in Chinese General Population: A Cross-Sectional Study

Authors: Qingzheng Wu, Yu Cheng, Hongyan Liu, Bing Li, Yiming Mu

Journal: Journal of Diabetes

Year: 2025

The Efficacy and Safety of iGlarLixi versus IDegAsp in Chinese Patients with Type 2 Diabetes Suboptimally Controlled with Oral Antidiabetic Drugs: Interpretation of the Soli-D Study

Authors: Ming Liu, Weijun Gu, Li Chen, Yanbing Li, Hongyu Kuang, Jianling Du, Agustina Alvarez, Felipe Lauand, Elisabeth Souhami, Jiewen Zhang, Weiya Xu, Qin Du, Yiming Mu

Journal: Diabetes, Obesity & Metabolism

Year: 2024

Christina Antza | Hypertension | Best Research Article Award

Posted on by Pencis

Assist. Prof. Dr. Christina Antza | Hypertension | Best Research Article Award

Assist. Prof. Dr. Christina Antza, 3rd Department of Internal Medicine, Aristotle University of Thessaloniki, Greece

Assist. Prof. Dr. Christina Antza is a specialist in Internal Medicine and Hypertension at the 3rd Department of Internal Medicine, Aristotle University of Thessaloniki, Greece. She holds an M.D., a Ph.D. in blood pressure measurement methods, and an M.Sc. in Research Methodology. Dr. Antza has extensive experience in hypertension, metabolic syndrome, diabetes, and atherosclerosis. She has worked as a researcher, consultant, and medical educator in Greece and the UK. Recognized with multiple awards and fellowships, she actively contributes to international medical research and education, shaping advancements in cardiovascular and metabolic disease management.

AUTHOR PROFILE

Orcid Profile

🎓 EARLY ACADEMIC PURSUITS:

Dr. Christina Antza began her educational journey at the Fifth High-School of Drama (Junior High School) and Third High School of Drama (Senior High School). She then pursued her Medical Degree at Aristotle University of Thessaloniki, Greece (2007-2013), graduating with an impressive 8/10 grade.

Her passion for research and academia led her to further studies, including:

  • Ph.D. in Internal Medicine (2014-2019) – Focused on blood pressure measurement methods and their ability to predict early vascular aging. She earned a Grade A with Distinction under the supervision of Prof. V. Kotsis.
  • Master of Science in Research Methodology in Medicine and Health Science (2016-2018) – Achieved an outstanding 9/10 grade.
  • Research Fellowship (2019-2020) – Conducted clinical and research work in Diabetes Mellitus and Obesity at the University of Birmingham, UK.
  • Postdoctoral Research (2019-2022) – Specialized in Hypertension and Metabolic Syndrome at Aristotle University of Thessaloniki.
  • Internal Medicine Consultant Certification (2021) – Earned after passing rigorous written and oral examinations.

💼 PROFESSIONAL ENDEAVORS:

Dr. Antza has held various prestigious roles in internal medicine, focusing on hypertension, metabolic syndrome, and endocrinology:

  • Scientific Associate (2013-2014) – Engaged in research and clinical practice in hypertension at the 3rd Department of Internal Medicine, Aristotle University of Thessaloniki.
  • Medical Resident (2016-2021) – Trained at Papageorgiou General Hospital, Aristotle University of Thessaloniki.
  • Academic Fellowship in Hypertension & Metabolic Syndrome (2021-2022) – Focused on clinical practice, independent teaching, and research.
  • Internal Medicine Consultant (2021-2023) – Served at Papageorgiou General Hospital and Bioclinic, offering expertise in hypertension, diabetes, and emergency medicine.
  • Assistant Professor of Internal Medicine – Hypertension (2023-Present) – Currently educating future medical professionals and leading research at Aristotle University of Thessaloniki.

Additionally, she has participated as a Subinvestigator in Phase 2 & 3 Clinical Trials, contributing to advancements in hypertension and metabolic disorders.

📚 CONTRIBUTIONS AND RESEARCH FOCUS ON HYPERTENSION:

Dr. Antza has extensively researched hypertension, metabolic syndrome, diabetes, lipid disorders, and vascular aging. Her work has focused on:

  • Blood Pressure Measurement Techniques (Home, Ambulatory, and Clinical).
  • Atherosclerosis and Cardiovascular Risk.
  • Metabolic Syndrome and Obesity-Related Disorders.
  • Diabetes and Endocrine Disorders.

She has been actively involved in research collaborations with leading medical institutions, including Queen Elizabeth Hospital, Birmingham, UK, where she served as an Honorary Observer (2019-2022) in the Endocrinology Department.

🏆 IMPACT AND INFLUENCE:

Dr. Antza’s work has been recognized with numerous awards and fellowships:

  • Young Fellow of the European Atherosclerosis Society (2019-Present).
  • Young Fellow of the European Hypertension Society (2023-Present).
  • Recipient of multiple Investigator Grants & Travel Awards from the European Society of Hypertension (ESH) and European Atherosclerosis Society (EAS).
  • 1st Place Oral Presentation Award – 8th Panhellenic Congress of the Hellenic Atherosclerosis Society (2019).
  • 2nd Clinical Research Award – 9th Panhellenic Congress of the Hellenic Atherosclerosis Society (2020).
  • Young Investigator Fellowship Award – 89th EAS Virtual Congress (2021).

📖 ACADEMIC CITATIONS & SCHOLARSHIPS:

Dr. Antza’s research has been widely cited in medical literature, influencing clinical guidelines in hypertension and metabolic diseases. Her scholarly excellence has earned her:

  • Ph.D. Scholarship from the Hellenic Society of Atherosclerosis (2014-2015).
  • Postdoctoral Research Scholarship from the State Scholarship Foundation (2019-2021).
  • Award from the Medical Sciences Deanery for Ph.D. Research (2020).

🌍 LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Christina Antza is poised to make significant future contributions in the diagnosis and management of hypertension, metabolic syndrome, and cardiovascular diseases. Her expertise in clinical research, education, and innovative treatment strategies will continue to shape internal medicine and patient care.

Her future goals include:
✔ Expanding research on hypertension-related complications and vascular aging.
✔ Leading international collaborations in cardiovascular and metabolic diseases.
✔ Mentoring the next generation of medical professionals and researchers.
✔ Contributing to global guidelines on hypertension and cardiovascular risk management.

Her dedication to patient care, research, and teaching makes her an influential figure in modern internal medicine and hypertension research.

🌟CONCLUSION :

Assist. Prof. Dr. Christina Antza is a dedicated clinician, researcher, and educator in the fields of hypertension, metabolic syndrome, and internal medicine. With a strong academic foundation, international research collaborations, and numerous accolades, she continues to advance medical knowledge and improve patient care. Her contributions to medical education and research have made a lasting impact, inspiring future generations of physicians. As she progresses in her career, Dr. Antza remains committed to innovation, scientific discovery, and excellence in healthcare, shaping the future of cardiovascular and metabolic disease management. Her work stands as a testament to dedication and expertise.

TOP NOTABLE PUBLICATIONS

Clinic, Ambulatory and Home Blood Pressure Monitoring for Metabolic Syndrome: Time to Change the Definition?

Journal: Medicina

Year: 2025

The Microbial Perspective: A Systematic Literature Review on Hypertension and Gut Microbiota

Journal: Nutrients

Year: 2024

The Effects of Olive Oil Consumption on Biochemical Parameters and Body Mass Index of People with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal: Nutrients

Year: 2024

Familial Hypercholesterolemia in the Elderly: An Analysis of Clinical Profile and Atherosclerotic Cardiovascular Disease Burden from the Hellas-FH Registry

Journal: Biomedicines

Year: 2024

The Modern Environment: The New Secondary Cause of Hypertension?

Journal: Medicina

Year: 2023

The Importance of Out-of-Office Blood Pressure Measurement, as Highlighted by the Correlation with Left Ventricular Hypertrophy in an Untreated Hypertensive Population

Journal: Medicina

Year: 2023